Abstract 194P
Background
In cases of persistent inflammation, the migration of immune cells follow the organogenesis of secondary lymphoid organs (SLO) within the organs, leading to the formation of tertiary lymphoid structures (TLS). These structures have become important as diagnostic and prognostic markers in chronic diseases and cancers. However, there is ongoing debate regarding how to assess the maturation of TLS in tissue samples, both in terms of determining the stages themselves and achieving agreement among pathologists. Based on the composition and organization of TLS revealed through imaging mass cytometry (IMC), we aimed to propose a reproducible classification system consisting of three maturation stages for TLS, which can be applied in pathology practice.
Methods
We used formalin-fixed and paraffin-embedded gastric samples (45 tissues with 134 TLS) and colonic samples (50 tissues with 159 TLS), representing inflammatory, cancerous, and control conditions. These samples were subjected to IMC analysis using a panel of 39 markers. Additionally, we sought correlations between markers that reflect the maturation of TLS (composition and architecture). The two IMC-markers with the strongest correlation with TLS maturation were selected to transfer the TLS maturation staging from IMC to dual-staining immunohistochemistry (IHC). This transfer was done to investigate the level of agreement among pathologists when classifying TLS using a set of 60 tissue IHC images.
Results
Using IMC, we were able to characterize the maturation of TLS and propose three distinct stages: Early TLS, Primary Follicle-Like TLS, and Secondary Follicle-Like TLS, identified as IHC CD21-CD23-, CD21+CD23-, and CD21+CD23+, respectively. The analysis of the 60 dual CD21-CD23 IHC images by three pathologists showed a high level of inter-pathologist agreement in classifying TLS into the three maturation stages (Cohen’s Kappa values: > 0.8).
Conclusions
With a strong correlation to cellular and architectural changes during TLS maturation, the dual CD21-CD23 IHC marker allows for the staging of TLS in tissue samples with a high level of inter-pathologist agreement, which holds potential for prognostic and predictive purposes.
Legal entity responsible for the study
M. Le Rochais.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display